PD-L1 Inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer in PD-L1 positive patients: a safety data network meta-analysis

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author García-Campelo, Rosario
• dc.contributor.author Arriola Aperribay, Edurne
• dc.contributor.author Campos Balea, Begoña
• dc.contributor.author López-Brea, Marta
• dc.contributor.author Fuentes-Pradera, José
• dc.contributor.author De Castro, Javier
• dc.contributor.author Aguado, Carlos
• dc.contributor.author Pérez Parente, Diego
• dc.contributor.author de Oro Pulido, Fidel
• dc.contributor.author Ruiz-Gracia, Pedro
• dc.contributor.author Rodríguez-Abreu, Delvys
• dc.date.accessioned 2022-06-22T06:55:41Z
• dc.date.available 2022-06-22T06:55:41Z
• dc.date.issued 2021
• dc.description.abstract This network meta-analysis (NMA) evaluates the safety of first-line programmed death-ligand 1 (PD-L1) inhibitor monotherapy in advanced NSCLC patients compared to platinum-based chemotherapy. We also compared the risk of adverse events (AEs) according to programmed cell death-1 receptor (PD-1) or PD-L1 inhibitors therapy. To that end, we conducted a series of metanalyses (MAs) using data from six phase III clinical trials, including 4053 patients. Our results show a reduced risk of any grade treatment-related AEs (risk ratio (RR) = 0.722 95% CI: 0.667-0.783, p = 0.002), and grade 3-5 AEs (RR = 0.406 95% CI: 0.340-0.485, p = 0.023) in immunotherapy as compared to chemotherapy. In contrast, a higher risk of immune-related AEs (irAEs) was estimated for immunotherapy versus chemotherapy. The subgroup MAs comparing PD-L1 to PD-1 inhibitors, determined a lower risk of AEs leading to treatment discontinuation in the anti-PD-L1 subgroup (RR = 0.47 95% CI: 0.29-0.75, p = 0.001); however, this statistically significant difference between anti-PD-L1 and anti-PD-1 subgroups was not reached for other safety outcomes analyzed. In conclusion, our findings show that PD-L1 inhibitor monotherapy improves safety outcomes in the 1L treatment of advanced NSCLC patients as compared to chemotherapy except for irAEs.
• dc.format.mimetype application/pdf
• dc.identifier.citation García Campelo MR, Arriola E, Campos Balea B, López-Brea M, Fuentes-Pradera J, de Castro Carpeno J, et al. PD-L1 Inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer in PD-L1 positive patients: a safety data network meta-analysis. J Clin Med. 2021 Oct 4; 10(19): 4583. DOI: 10.3390/jcm10194583.
• dc.identifier.doi http://dx.doi.org/10.3390/jcm10194583
• dc.identifier.issn 2077-0383
• dc.identifier.uri http://hdl.handle.net/10230/53558
• dc.language.iso eng
• dc.publisher MDPI
• dc.rights Copyright © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword PD-L1 inhibitors
• dc.subject.keyword First-line treatment
• dc.subject.keyword Immunotherapy
• dc.subject.keyword Network meta-analysis
• dc.subject.keyword Non-small cell lung cancer
• dc.subject.keyword Safety
• dc.title PD-L1 Inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer in PD-L1 positive patients: a safety data network meta-analysis
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion